Arensia Exploratory Medicine Llc

Tbilisi 0112

3 studies enrolling now · 13 studies all time

What they study most

Acute Myeloid Leukemia (AML), Advanced Breast Cancer, B-cell Malignancy, Breast Cancer, Breast Cancer Female, Breast Carcinoma, Breast Neoplasm, Carcinoma, Ductal, Breast, Chronic Lymphocytic Leukemia, Diffuse Large B Cell Lymphoma, Diffuse Large B Cell Lymphoma (DLBCL), Extensive-stage Small Cell Lung Cancer (ES-SCLC)

Studies at this site

• DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemotherapy — Recruiting now
• A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies — Recruiting now
• Study of GS-0151 in Participants With Rheumatoid Arthritis — Recruiting now
• A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus — Recruiting now
• Study in Metastatic Breast Cancer Patients Receiving Eftilagimod Alpha or Placebo in Combination With Paclitaxel Chemotherapy — Stopped early
• A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps People With Head and Neck Cancer Compared With Pembrolizumab Alone — Running, not enrolling
• A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma — Running, not enrolling
• Study of GS-0272 in Participants With Rheumatoid Arthritis — Stopped early
• GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies — Stopped early
• A Study of Lerociclib in Participants With Advanced Breast Cancer — Stopped early
• A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer — Running, not enrolling
• G1T48, an Oral SERD, Alone and in Combination With Palbociclib in ER-Positive, HER2-Negative Advanced Breast Cancer — Completed
• Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Etoposide and Carboplatin in Extensive Stage Small Cell Lung Cancer (SCLC) — Completed